Progyny (NASDAQ:PGNY) Announces Quarterly Earnings Results

Progyny (NASDAQ:PGNY) issued its quarterly earnings data on Thursday. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.24), Zacks reports. Progyny had a return on equity of 11.23% and a net margin of 4.46%.The business had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. During the same period in the previous year, the business earned $0.11 earnings per share. The business’s quarterly revenue was up 9.3% on a year-over-year basis. Progyny updated its FY 2025 guidance to 1.790-1.820 EPS and its Q4 2025 guidance to 0.370-0.400 EPS.

Progyny Stock Performance

PGNY stock traded up $4.36 during midday trading on Friday, reaching $22.37. The company’s stock had a trading volume of 4,589,860 shares, compared to its average volume of 1,669,160. Progyny has a 1 year low of $13.39 and a 1 year high of $26.76. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 35.51, a PEG ratio of 1.53 and a beta of 1.29. The stock has a fifty day simple moving average of $20.91 and a two-hundred day simple moving average of $21.85.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PGNY. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price objective (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Raymond James Financial set a $28.00 target price on Progyny in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their target price on Progyny from $23.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, August 26th. Finally, Canaccord Genuity Group raised their price target on Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.44.

Insider Transactions at Progyny

In related news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the business’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 7,895 shares of company stock worth $179,311. Company insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Progyny

Hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. boosted its stake in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in Progyny during the second quarter worth $4,670,000. Cubist Systematic Strategies LLC lifted its holdings in Progyny by 432.6% during the second quarter. Cubist Systematic Strategies LLC now owns 242,361 shares of the company’s stock worth $5,332,000 after buying an additional 196,856 shares during the period. Jump Financial LLC bought a new stake in Progyny during the 2nd quarter valued at $3,262,000. Finally, Qube Research & Technologies Ltd increased its holdings in shares of Progyny by 375.2% in the 2nd quarter. Qube Research & Technologies Ltd now owns 174,693 shares of the company’s stock valued at $3,843,000 after acquiring an additional 137,928 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.